Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Oric Pharmaceuticals, Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][4]. - The recent upgrade reflects an improvement in Oric Pharmaceuticals' earnings outlook, which is expected to positively affect its stock price [3][5]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Oric Pharmaceuticals is projected to earn -$1.61 per share, unchanged from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Oric Pharmaceuticals has increased by 6.6%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimates, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, highlighting their potential for market-beating returns [9][10]. - Oric Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a favorable outlook for the stock in the near term [10].